A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk.
Jiani Wang(Hubei University of Technology), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuxin Mu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiayu Wang(Nanjing University of Chinese Medicine), Qiao Li(Guangzhou University of Chinese Medicine), Qing Li(Army Medical University), Yang Luo(Chongqing University of Posts and Telecommunications), Tongtong Zhang(Jiangsu Province Hospital), Pin Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Fan(Hebei North University), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Han(Fujian University of Traditional Chinese Medicine), Peng Yuan(Zhengzhou University)
Cited by 7
Related Papers
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
|Signal Transduction and Targeted Therapy|2019|406
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
|Nature Immunology|2021|374
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287